ASTM F1027-1986(2017) Standard Practice for Assessment of Tissue and Cell Compatibility of Orofacial Prosthetic Materials and Devices《评估面部假体材料和设备的组织和细胞相容性的标准实施规程》.pdf

《ASTM F1027-1986(2017) Standard Practice for Assessment of Tissue and Cell Compatibility of Orofacial Prosthetic Materials and Devices《评估面部假体材料和设备的组织和细胞相容性的标准实施规程》.pdf》由会员分享，可在线阅读，更多相关《ASTM F1027-1986(2017) Standard Practice for Assessment of Tissue and Cell Compatibility of Orofacial Prosthetic Materials and Devices《评估面部假体材料和设备的组织和细胞相容性的标准实施规程》.pdf（11页珍藏版）》请在麦多课文档分享上搜索。

1、Designation: F1027 86 (Reapproved 2017)Standard Practice forAssessment of Tissue and Cell Compatibility of OrofacialProsthetic Materials and Devices1This standard is issued under the fixed designation F1027; the number immediately following the designation indicates the year oforiginal adoption or,

2、in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. Asuperscript epsilon () indicates an editorial change since the last revision or reapproval.1. Scope1.1 This practice describes a procedure to assess the cyto-toxic potential of materia

3、ls for use in the construction ofmedical materials and devices using human excised donor(HED) tissues and their derived primary cells taken from theorofacial region.1.2 This practice may be used either directly to evaluatematerials or as a reference against which other cytotoxicitymethods may be com

4、pared.1.3 This practice is one of a series of reference methods forassessment of cytotoxic potential, employing different tech-niques.1.4 Assessment of cytotoxicity is one of several proceduresemployed in determining the biological response to a material,as recommended in Practice F748.1.5 This stan

5、dard does not purport to address all of thesafety concerns, if any, associated with its use. It is theresponsibility of the user of this standard to establish appro-priate safety and health practices and determine the applica-bility of regulatory limitations prior to use.1.6 This international stand

6、ard was developed in accor-dance with internationally recognized principles on standard-ization established in the Decision on Principles for theDevelopment of International Standards, Guides and Recom-mendations issued by the World Trade Organization TechnicalBarriers to Trade (TBT) Committee.2. Re

7、ferenced Documents2.1 ASTM Standards:2D883 Terminology Relating to PlasticsF604 Specification for Silicone Elastomers Used in MedicalApplications (Withdrawn 2001)3F703 Specification for Implantable Breast Prostheses (With-drawn 2016)3F748 Practice for Selecting Generic Biological Test Methodsfor Mat

8、erials and DevicesF813 Practice for Direct Contact Cell Culture Evaluation ofMaterials for Medical Devices3. Terminology3.1 Nomenclature relating to the physical, mechanical, andchemical characteristics of plastics shall be in accordance withTerminology D883.3.2 The nomenclature and glossary of term

9、s related to tissueculturing shall conform to that of the Tissue Culture Associa-tion (1).43.3 For other definitions used in this practice, see AnnexA1.4. Summary of Practice4.1 Primary human orofacial tissue or cells and establishedhuman cell lines are cultured in Medium A3 or any mediumsupporting

10、primary cell growth with homologous processedhuman serum or serum components in cell culture flasks orappropriate containers. The following series of cultures is setup:4.1.1 Test material placed in contact with the cell layer.NOTE 1One or more replicates of 4.1.1 may be necessary.4.1.2 Primary contr

11、ol wherein no material contacts the celllayer.4.1.3 Positive control wherein the cell layer is contacted bya material eliciting a known cytotoxic response, such as a toxicchemical published in the Toxic Substances List (2).4.1.4 Negative control wherein the cell layer is contacted bypolystyrene used

12、 in tissue culture labware.4.2 The test culture shall be observed daily for growth andsigns of toxicity. The test shall be terminated upon theattainment of confluency.1This practice is under the jurisdiction ofASTM Committee F04 on Medical andSurgical Materials and Devices and is the direct responsi

13、bility of SubcommitteeF04.16 on Biocompatibility Test Methods.Current edition approved Nov. 1, 2017. Published November 2017. Originallyapproved in 1986. Last previous edition approved in 2012 as F1027 86 (2012).DOI: 10.1520/F1027-86R17.2For referenced ASTM standards, visit the ASTM website, www.ast

14、m.org, orcontact ASTM Customer Service at serviceastm.org. For Annual Book of ASTMStandards volume information, refer to the standards Document Summary page onthe ASTM website.3The last approved version of this historical standard is referenced onwww.astm.org.4The boldface numbers in parentheses ref

15、er to the list of references at the end ofthis practice.Copyright ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United StatesThis international standard was developed in accordance with internationally recognized principles on standardization established i

16、n the Decision on Principles for theDevelopment of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.1NOTE 2For an established cell line cultured with Holmes alphagrowth factor (AGF), confluency is usually achieved

17、in slightly more than5 days.NOTE 3For first passage cells from HED cultures, confluency isusually achieved between 10 to 20 days with an upper limit of 30 days.5. Significance and Use5.1 This practice is useful for assessing the cytotoxicpotential both when evaluating new materials or formulationsfo

18、r possible use in medical applications, and as part of a qualitycontrol program for established medical devices.5.2 This practice is used for assessing the cytotoxic poten-tial of materials intended for the fabrication of inserts orimplants in the orofacial region.5.3 This practice is restricted to

19、normal non-transformed,human orofacial tissues using cells cultured in human serumfactors and does not depend upon cells and serum fromnon-human sources.5.4 This practice incorporates procedures to monitor thequality of ingredient materials and the uniformity of theproduction process for formulating

20、 stock compositions.5.5 This practice may be useful to determine the effects ofage and radiation, and the state of carcinogenicity on thesensitivity of HED tissues to materials and devices used fororofacial prostheses.6. Apparatus6.1 Incubator, capable of maintaining a temperature of 37 61C and an a

21、tmosphere of 95 % air and 5 % CO2with at least90 % relative humidity.6.2 Plastic and Glassware, that is specified by chemicaltype and is traceable to its source of supply by catalog numberor trade designation of the manufacturer or vendor.6.3 Laminar Flow Cabinet, that meets the Class 100 cleanroom

22、requirements of the U. S. Federal Standard 209B or theNational Standard Foundation Standard NSF 49.6.4 Fluid Filters, capable of removing 95 % of particles0.22 m or larger.6.5 Water Purification System, with filtration capability fororganic contaminants, capable of producing water with resis-tivity

23、of 18 M-cm or greater.6.6 Inverted Stage Microscope, with phase contrast optics.6.7 Bright Field Microscope, or a photomicroscope withmagnification to 200.7. Reagents7.1 Medium A3Chemically defined medium A3 describedby Holmes (3).NOTE 4Other chemically defined media shall be acceptable providedthe

24、test human cell adapts within 1 to 3 days to a steady growth rate fromlow cell density for a period of 7 to 30 days.7.2 Trypsin 0.25 % Solution, stored in lyophilized form at 3to 5C. A solution may be prepared as needed and used at37C.7.3 Insulin, 6.6 U/100 mL, used as supplement for primarycell and

25、 cell line cultures.7.4 Miscellaneous Fixatives, dehydrating solutions, stains,and so forth, for making permanent record microscopic slides.8. Human Serum8.1 The human serum shall be processed in accordance withthe method described in Annex A2.NOTE 5The dialysis treatment serves to remove suspect to

26、xicants,ingested medication, unneeded adventitiae, and unidentified growth in-hibitants with exclusion up to a molecular weight of 3500 Daltons.9. Cell Growth Factors9.1 Alpha Growth Factor (AGF)AGF, separated from thedialyzed human serum as described in AnnexA3, shall be usedas needed to enhance ce

27、ll growth.NOTE 6Initially designated alpha-1-protein (4), AGF can be used inplace of whole serum to maintain the reference established cell line (ECL)cultures for the 7 to 30 day test period when added to a chemically definedmedium (See 7.1).10. Reference ECL Cells10.1 Human non-transformed establis

28、hed cell line (ECL)cell obtainable from a repository source, such as the AmericanType Culture Association (ATCC), shall be used as a referenceto monitor the procedural details for uniformity of the testingsystem and for indication of quality and reliability of culturemedium, human serum preparation,

29、 and quality of selectedgrowth factors.NOTE 7For interlaboratory comparison of these procedural details,the clinically accessible gingival orofacial tissue cell, as well as themucosal (nasal, maxillo, and so forth), shall be selected and appropriatelydesignated.11. (HED) Cells11.1 Human tissues of t

30、he orofacial region, obtained frompatient donors, shall be cultured as explants until sufficient celldensity is attained for succeeding passages into a valid primarycell line.12. Preparation of Specimens12.1 Aseptic techniques shall be used throughout the pro-cedure.12.2 Warm all solutions and mater

31、ials to a temperature of 376 2C before placing in contact with cells.12.3 Specimens:12.3.1 Test materials shall range from 0.1 to 1 mm inthickness, cut into square or triangular geometries, 10 to 15mm on a side.12.3.2 Test specimens shall be sterilized by the method usedin the preparation of the fin

32、ished device.12.3.3 The test arrangement must provide total immersionand immobilization of specimens (see Fig. 1).Apair of slots iscut in the specimen and a suitably cleaned cover glass (9 by 50mm, No. 1) is threaded through the slots. One or more roundholes (3 mm in diameter) are pre-cut in the cen

33、ter of thespecimen. This provides an area of high leaching concentrationas well as a focus for a photomicrographic record.F1027 86 (2017)2NOTE 8If contamination of the assembled test material-microslip issuspected, it may be autoclaved before insertion into a sterile culture flask.12.4 Conventional

34、practices of maintaining contaminant-free working conditions shall be applied in handling tissues,cells, and glassware with well-established techniques as al-ready prescribed in numerous texts and handbooks. In thisconnection, see the work by John Paul (5) as one of severaltexts dealing with prevent

35、ion of aerial and fluid contaminationin cell culture practices.13. Preparation of (ECL) Cultures13.1 The reference cell line (see 10.1) shall be routinelymaintained as stock cultures, either in completely chemicallydefined A3 medium or in Annex A3 medium containing thealpha growth factor (AGF), or i

36、n A3 medium supplementedwith 10 % processed human serum.13.2 Medium changes are made every 48 to 72 h or on atriweekly schedule, such as Mondays, Wednesdays, and Fri-days. Cultures are checked microscopically at the time andobserved for any morphological changes or contamination,delayed or incidenta

37、l.13.3 Cell stock cultures of established cell line are main-tained not only as source of cells for the biocompatibilityassessment but also as a means to ascertain and verify thequality and titer of the production lots of processed humanserum and preparation lots of separated AGF.14. Preparation and

38、 Maintenance of Primary HumanCells14.1 Place the human excised donor tissue (explant) ascep-tically onto a sterile petri dish holding gauze covered with A3medium containing 10 % processed human serum.14.2 Dissect explant immediately into small pieces, cut into1 to 2 mm thin slices approximately 2 to

39、 4 mm2in cross-sectional area.14.3 Incubate at 37 6 1Cina5%CO2and 95 % airatmosphere in quadruplicate series of culturing containers untila monolayer is formed and confirmed microscopically.14.4 Trypsinize with fresh, ready prepared 0.25 % trypsinsolution.NOTE 9Other methods of enzyme treatment may

40、be utilized providedthe outcome of the assay has been substantially equivalent.14.5 Place the trypsinized cells in sterile culture flasks toprepare a stock of first passage cells for the biocompatibilitytest (see Section 17).14.6 Check the first passage cultured cells for native con-tamination by vi

41、rus, bacteria, and pleuropneumonia-like organ-isms (PPLO). Discard if present and identified and replace withnew donor explants.NOTE 10Such microorganisms are often entrapped in oral mucosaltissues as contaminants, which could compromise the validity of the testresult by imposing foreign, nonspecifi

42、c cytotoxicity in the procedure inSection 17.14.7 Harvest the cultured propagated cells for use inamounts needed in 17.3. Store any unused portion in glycerolor dimethyl sulphoxide (DMSO) at 70C for new sets of tests,using the procedure described in Chapter XIX of Ref. 5.15. Ascertaining Minimum Eff

43、ective Titer of GrowthFactor15.1 The selected reference human ECL cell shall beadapted to grow in the Holmes A3 medium or in a culturingmedium of equivalent effectiveness using:15.1.1 Initial low density cell level of 103to 104cells/mL,15.1.2 One percent processed (Annex A2) human serum,15.1.3 A ser

44、ies of alpha growth factor comprising 0, 0.1,1.0, and 10 g (dry basis) per millilitre of media.15.1.4 Grown to confluent monolayer with a schedule ofthree fresh media maintenance replenishments per week asindicated in 13.2.NOTE 1Test specimens less than 1 mm in thickness tend to float. The figure de

45、picts one means of maintaining submerged contact between specimensand cell cultures.NOTE 2Dimensions and configuration of the hole, serving for initial cell seeding, may be optionally modified and appropriately specified.FIG. 1 Arrangement for Submersing and Immobilizing SpecimensF1027 86 (2017)3NOT

46、E 11It is essential to recognize the various phases of cell growth,which includes adaptation (I), usually with decreasing cell population forone or more days, followed by log growth (II), usually referred to inpopulation doubling time, leading to monolayer confluency (III), andultimately to decline

47、(IV) in cell population by reason of senescence ortoxicity. In this connection, appropriate, periodic cell counts to confluency(IV) can be applied as described by Lontz (6).15.2 Following the attained confluency in the above AGF 0to 10 g/mL range, the minimal supplementation by AGF isnoted for use i

48、n the ensuing procedure for biocompatibility ofprosthetic material samples (Section 17).16. Reference Control and Materials16.1 The negative control shall be a material that consis-tently does not inhibit cell growth as observed visibly or by anappropriate increase in cell count during growth to con

49、fluency.The following material may be used:16.1.1 USP Negative Control Plastic Reference Standard(7).16.1.2 Fluorocarbon film or sheeting.NOTE 12Satisfactory sheetings are Teflon FEP fluorocarbon, 10 mil(0.010 in.) in thickness and a copolymer of tetrafluorethylene andhexafluoropropylene of commercial prominence; This grade of fluorocar-bon polymer is uniquely useful because of (a) exceptional chemicalinertness, (b) high specific gravity, higher than most of the nutrient media,and (c) exceptional clarity for viewing cell structure.16.1.3 Polystyrene cul